1-3 of 3
Haocheng Li
Close
Sort by
Journal Articles

Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)

Franck Morschhauser, Krish Patel, Sabela Bobillo, Raul Cordoba, Toby A. Eyre, Mark Bishton, Roch Houot, Hui-Lai Zhang, Liqun Zou, Wendy Osborne, Laura Gálvez-Carvajal, Catherine Thieblemont, Donald Yee, Andrea Knapp, Enkhtsetseg Purev, Haocheng Li, Vivian Chen, Karl L. Banta, Jason Sit, Emmanuel Bachy
Journal: Blood
Blood (2023) 142 (Supplement 1): 605.
https://doi.org/10.1182/blood-2023-174432
Published: 2023
Journal Articles

Analysis of Immune Pharmacodynamic and Baseline Biomarkers in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Mosunetuzumab in Combination with Lenalidomide

Mark Bishton, Corinna Woestmann, Franck Morschhauser, Toby A. Eyre, Maria Shin, Aaron Schroeder, Anton Belousov, Haocheng Li, Andrea Knapp, Michael C. Wei, Enkhtsetseg Purev, Alessia Bottos
Journal: Blood
Blood (2022) 140 (Supplement 1): 3555–3556.
https://doi.org/10.1182/blood-2022-157256
Published: 2022
Journal Articles

Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study

Franck Morschhauser, Mark Bishton, Toby A. Eyre, Emmanuel Bachy, Guillaume Cartron, Loïc Ysebaert, Sabela Bobillo, Norma C. Gutierrez, L. Elizabeth Budde, Christopher P. Fox, Andrea Knapp, Manejeh Yaqub, Michael C. Wei, Carol O'Hear, Haocheng Li, Enkhtsetseg Purev, William Townsend
Journal: Blood
Blood (2021) 138 (Supplement 1): 129.
https://doi.org/10.1182/blood-2021-145694
Published: 2021